P. Gestraud

Integrated multiomic profiling reveals SWI/SNF subunit-specific pathway alterations and targetable vulnerabilities

The paper identifies pathway alterations and targetable vulnerabilities in SWI/SNF-defective cancers through multiomic profiling and drug screening.

COMBINATION THERAPIES TARGETING ALK-ABERRANT NEUROBLASTOMA IN PRECLINICAL MODELS.

This study evaluates lorlatinib, an ALK inhibitor, in combination with chemotherapy or idasanutlin in preclinical neuroblastoma models, finding synergy in models with high ALK expression.

Discovery of a druggable copper-signaling pathway that drives cell plasticity and inflammation

The paper identifies a copper-signaling pathway involving CD44 and mitochondrial copper(II) that drives inflammation and cell plasticity, and shows a metformin-based drug reduces inflammation in infection models.

Low centrosome numbers correlate with higher aggressivity in ovarian cancer

The paper analyzes centrosome numbers in ovarian cancers and finds that low centrosome numbers correlate with poor patient survival and mesenchymal subgroup enrichment.

In vivo genome-wide CRISPR screens identify SOCS1 as a major intrinsic checkpoint of CD4+ Th1 cell response

The paper identifies SOCS1 as a key intrinsic checkpoint limiting CD4+ Th1 cell response through in vivo CRISPR screens and shows targeting SOCS1 enhances antitumor T-cell therapy.

Differential screening identifies molecules specifically inhibiting CCR5 transport to the cell surface and HIV infection

The paper identifies molecules that inhibit CCR5 transport to the cell surface and HIV infection by targeting palmitoylation.